|Send to printer »|
Legal Affairs : Sep 1, 2012 ( )
Biosimilars Now Just About Ready to Roll
Supreme Court Decision Left BPCI Intact, Clearing Pathway for FDA Final Ruling!--h2>
Following the U.S. Supreme Court’s decision to leave intact the Patent Protection and Affordable Care Act, the development of biosimilars to treat a wide variety of diseases and health conditions is poised to surge. The Act contains important provisions that create a pathway for the FDA to approve “biosimilar” versions of previously approved biotechnology drugs.
The Act created an abbreviated licensure pathway for biological products in the part of the law known as the Biologics Price Competition and Innovation Act. Under the BPCI Act, a biological product may be demonstrated to be “biosimilar” if data shows that, among other things, the product is “highly similar” to an already approved biological product.
The U.S. Supreme Court, in upholding the legislation, also removed the uncertainty over the immediate future of biosimilars. Now, biotech and pharmaceutical companies will likely quicken an already accelerating pace of partnership agreements, mergers and acquisitions, and technology deals to enable the production of biosimilars. The stakes are high:
The battleground over biosimilars is expected to move next to the scope of clinical trials required by the FDA—which promises to be a hotly contested issue. Biologic License Application (BLA) holders will contend that certain studies are required to maintain safety while biosimilar applicants will argue that extensive studies are not needed since those studies have already been conducted for the original product, and that the differences between the biosimilar product and the reference product are sufficient to establish clinical similarity, without repeating the clinical studies carried out with the reference product.
The industry is waiting for final rulemaking from FDA, and biosimilar applications are expected to be filed with the FDA shortly thereafter.
In February 2012, the FDA issued three draft guidance documents on biosimilar product development regarding key scientific and regulatory factors involved in submitting applications for biosimilar products to the agency:
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product:
The draft guidance is intended to assist companies in demonstrating that a proposed therapeutic protein product is biosimilar to a reference product for the purpose of submitting a 351(k) application to the FDA. This draft guidance describes a risk-based “totality-of-the-evidence” approach that the FDA intends to use to evaluate the data and information submitted in support of a determination of biosimilarity of the proposed product to the reference product.
Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product:
This guidance provides an overview of analytical factors to consider when assessing biosimilarity between a proposed therapeutic protein product and a reference product for the purpose of submitting a 351(k) application. This includes the importance of extensive analytical, physicochemical, and biological characterization in demonstrating that the proposed biosimilar product is highly similar to the reference product notwithstanding minor differences in clinically inactive components.
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009:
The draft provides answers to common questions from companies interested in developing biosimilar products. The question and answer format addresses questions that may arise in the early stages of product development, such as how to request meetings with the FDA, addressing differences in formulation from the reference product, how to request exclusivity, and other topics.
The FDA provided a 60-day period for stakeholders to offer comments. The comment period has ended and the FDA will issue final regulations, respond to comments, or both, later this year, probably in the third quarter.
The FDA received submissions from an array of stakeholders, including the Biotechnology Industry Organization (BIO). BIO has advocated that the FDA expand the requirements to prove biosimilarity significantly beyond the minimum tests mandatory in the statute, and generally recommends policies that make it more difficult to obtain expedited approval created under the BPCI Act.
Congressional intervention is unlikely at this stage. The Supreme Court’s upholding of the BPCI Act as part of the Affordable Care Act now clears the way for final FDA rulemaking and the beginning of a new era of U.S. healthcare that will include affordable biosimilar medicines.
© 2013 Genetic Engineering & Biotechnology News, All Rights Reserved